A phase 3 randomized, controlled, open-label study of selinexor, bortezomib, and dexamethasone (SVd) versus bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma (RRMM).
Details
Serval ID
serval:BIB_6D9EB4864E44
Type
Inproceedings: an article in a conference proceedings.
Publication sub-type
Abstract (Abstract): shot summary in a article that contain essentials elements presented during a scientific conference, lecture or from a poster.
Collection
Publications
Institution
Title
A phase 3 randomized, controlled, open-label study of selinexor, bortezomib, and dexamethasone (SVd) versus bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma (RRMM).
Title of the conference
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
ISSN
0732-183X
1527-7755
1527-7755
Publication state
Published
Issued date
20/05/2018
Volume
36
Number
15_suppl
Pages
TPS8056-TPS8056
Language
english
Web of science
Create date
02/12/2024 16:49
Last modification date
04/12/2024 7:07